AstraZeneca announced today that its antibody treatment has met its primary target in the final phase of clinical trials.
The therapy, which combines two types of antibodies originally discovered by Vanderbilt University Medical Center, has reduced the risk of developing symptomatic Covid-19 by 77%, the company said, citing British media.
The same report concluded that more than 75% of the participants in this study had chronic illnesses, including some with a reduced immune response to vaccinations.
The pharmaceutical company is also developing research to try to reuse existing drugs that could also fight the new coronavirus.
The data shows that a single dose of this drug can “quickly and effectively prevent the symptoms of COVID-19,” Myron Levin, lead researcher for the study, told AFP.
“With these promising results, AZD7442 could be an important tool to help people who may need more than a vaccine get back to their normal lives,” the expert explained.
The drug is expected to be used as an alternative or in conjunction with vaccines for those in need of more protection, providing up to 12 months of protection, the pharmacist announced.
